Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) Meeting Abstract


Authors: Chan, L. S.; Kudo, M.; Sangro, B.; Kelley, R. K.; Furuse, J.; Park, J. W.; Sunpaweravong, P.; Fasolo, A.; Yau, T.; Kawaoka, T.; Cheng, A. L.; Azevedo, S.; Reig Monzon, M. E.; Assenat, E.; Yarchoan, M.; He, A. R.; Makowsky, M.; Ran, D.; Negro, A.; Abou-Alfa, G. K.
Abstract Title: Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Meeting Title: ESMO Congress 2022
Journal Title: Annals of Oncology
Volume: 33
Issue: Suppl. 7
Meeting Dates: 2022 Sep 9-13
Meeting Location: Paris, France
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2022-09-01
Start Page: S869
End Page: S870
Language: English
ACCESSION: WOS:000866211600705
DOI: 10.1016/j.annonc.2022.07.838
PROVIDER: wos
Notes: Meeting Abstract: 714P -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ghassan Abou-Alfa
    568 Abou-Alfa